Abstract
Targeted therapy with conjugated and unconjugated monoclonal antibodies for non-Hodgkin's lymphoma has revolutionized the approach to this disease. The efficacy and low toxicity of these agents have allowed introduction of this strategy in the early stages of therapy. Longer follow-up is needed before validating the safety of these agents. Since monoclonal antibodies are being given as front-line therapy, it is important to identify all potential adverse events. We report a case of secondary acute myelogenous leukemia (AML) with 11q23 cytogenetic abnormality and mixed lymphoid leukemia (MLL) gene expression in a patient treated with Y90 labeled anti-CD20 antibody (Zevalin). The patient was not exposed to topoisomerase II inhibitors. Our observations suggest a relationship between 11q23 leukemia and radioimmunotherapy (RAIT) and further studies are needed.
Original language | English (US) |
---|---|
Pages (from-to) | 2145-2149 |
Number of pages | 5 |
Journal | Leukemia and Lymphoma |
Volume | 43 |
Issue number | 11 |
DOIs | |
State | Published - Nov 1 2002 |
Funding
This work was supported in part by the clinical oncology training grant (5T32 CA79447-03) from the National Cancer Institute.
Keywords
- Acute myelogenous leukemia
- MLL gene rearrangement
- Radioimmunotherapy
- Secondary leukemia
- Zevalin
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research